Replimune Group (NASDAQ:REPL) Shares Gap Up – Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL) shares gapped up prior to trading on Friday . The stock had previously closed at $4.68, but opened at $7.93. Replimune Group shares last traded at $8.3250, with a volume of 19,835,009 shares traded.

Analyst Ratings Changes

A number of equities analysts recently commented on REPL shares. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Wedbush reiterated a “neutral” rating and set a $2.00 price target (down from $19.00) on shares of Replimune Group in a report on Monday, April 13th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Replimune Group in a research note on Monday, April 13th. BMO Capital Markets cut Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $2.00 price target (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Six analysts have rated the stock with a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $4.75.

Replimune Group Stock Performance

The company has a market cap of $709.28 million, a PE ratio of -2.52 and a beta of 0.12. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The company’s fifty day moving average price is $4.84 and its 200 day moving average price is $7.25.

Insider Buying and Selling

In other news, insider Christopher Sarchi sold 6,500 shares of the firm’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total transaction of $52,065.00. Following the sale, the insider directly owned 151,588 shares in the company, valued at $1,214,219.88. This trade represents a 4.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by insiders.

Institutional Trading of Replimune Group

Large investors have recently made changes to their positions in the business. International Assets Investment Management LLC bought a new position in shares of Replimune Group during the fourth quarter valued at approximately $29,000. CWM LLC raised its stake in shares of Replimune Group by 248.6% in the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after purchasing an additional 2,886 shares during the last quarter. Essential Partners LLC lifted its position in Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after purchasing an additional 5,624 shares during the period. BNP Paribas Financial Markets raised its position in Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after acquiring an additional 1,879 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Replimune Group in the second quarter valued at $69,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.